Exchange: NASDAQ·Updated 07:57 AM EDT
PROK logo

PROK ProKidney Corp

$1.80
$0.03
(1.64%)
Pre-Market
Prev Close $1.83
Reported EarningsAug 10
Mkt Cap$553.25M
Vol14.00

About PROK

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
50

Neutral Sentiment

How do you feel about PROK?

Advertisement|Remove ads.